At a glance
ClinicalIndex Comparison RecordPhase 2Recruiting· 228 target
Drug / intervention
AL8326 tablets +1 moredrug
Likely dose
AL8326 tablets 10mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I/IIa Clinical Trial of AL8326 Tablets Combined With Toripalimab in the Treatment of Advanced Recurrent or Metastatic Solid Tumors
In Brief
A Phase 2 clinical trial evaluating AL8326 tablets and Toripalimab for Solid Tumor. Currently recruiting, targeting 228 participants across 15 sites.
Signals
Enrolling ahead of pace
Detailed Summary
This trial is an open, non-randomized, phase I/IIa clinical trial, which will evaluate the preliminary effectiveness and safety of AL8326 tablets in patients with advanced solid tumors
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSolid Tumor
CountriesChina
Collaborators--
Timeline
Phase 2Recruiting
202220232024202520262027202820292030
Enrollment StartOct 2021
First PostedFeb 2026
TodayJul 2026
Primary CompletionNov 2029
First PostedFeb 6, 2026
Enrollment StartOct 26, 2021
Primary CompletionNov 7, 2029
TodayJul 1, 2026
Enrollment to primary: 8.0 yearsPosted 5 months agoPrimary completion in 3.4 years
Interventions
AL8326 tabletsdrug
Tablet: 10mg/tablet; administered orally once daily
Toripalimabdrug
240mg Injection solution：21-Day cycles